Gemdo Warning Letter Speaks Volumes About FDA Concerns, Industry Challenges
This article was originally published in The Rose Sheet
There is much for cosmetic stakeholders to take away from FDA’s April 16 warning letter to Gemdo Cosmetics Inc., which highlights some key enforcement priorities at the agency and topline issues currently facing the industry as a whole.
You may also be interested in...
G&S, which manufactures personal-care products for hotels and spas worldwide, recalled more than 2 million potentially contaminated units of bath and body products last year, but its regulatory compliance issues are not behind it yet. In a March 16 warning letter, FDA cites the firm for inspection failings and product sample analyses that render its products adulterated under US cosmetics law.
Infographic – An analysis by "The Rose Sheet" of FDA data from 2011-2015 finds bacterial or mold contamination to be the most frequently cited rationale for cosmetic recalls reported during the five-year period. Click the buttons in the interactive graphic below to view and compare data.
Support grows for federal bills to ban cosmetic animal testing and use of synthetic plastic microbeads in the U.S. More news in brief.